Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Newron Pharmaceuticals SpA's enterprise value is €282.64 Mil.
Newron Pharmaceuticals SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.78 Mil. Therefore, Newron Pharmaceuticals SpA's EV-to-EBITDA for today is -36.31.
The historical rank and industry rank for Newron Pharmaceuticals SpA's EV-to-EBITDA or its related term are showing as below:
FRA:NP5'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -84.74 Med: -6.28 Max: 21.66
Current: -35.48
During the past 13 years, the highest EV-to-EBITDA of Newron Pharmaceuticals SpA was 21.66. The lowest was -84.74. And the median was -6.28.
FRA:NP5's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs FRA:NP5: -35.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Newron Pharmaceuticals SpA's PE Ratio (TTM) for today is calculated as:
Newron Pharmaceuticals SpA's share price for today is €12.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NP5 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's EV-to-EBITDA falls into.
Newron Pharmaceuticals SpA's current Enterprise Value is €282.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA (FRA:NP5) has a EV-to-EBITDA of -36.31 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Newron Pharmaceuticals SpA. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #999999 out of 409 companies in the Biotechnology industry.
Is Newron Pharmaceuticals SpA's EV-to-EBITDA too high?
Newron Pharmaceuticals SpA's current EV-to-EBITDA is -36.31. Based on the distribution chart, Newron Pharmaceuticals SpA ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #999999 out of 409 companies for EV-to-EBITDA. This places Newron Pharmaceuticals SpA in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Newron Pharmaceuticals SpA. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newron Pharmaceuticals SpA's current EV-to-EBITDA is -36.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €13.90, compared to a current price of €12.60 — trading 9.4% below its estimated fair value. The current EV-to-EBITDA is -36.31. Newron Pharmaceuticals SpA's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current EV-to-EBITDA is -36.31 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued.
The current stock price of €12.60 is trading 9.4% below its estimated GF Value™ of €13.90.
GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.
Key valuation signals for FRA:NP5:
EV-to-EBITDA: -36.31
GF Value™: €13.90 vs. price of €12.60 (9.4% below fair value)
No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
75GF Score
Get the complete analysis for FRA:NP5
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NP5 has been successfully added to your 
